Mufemilast is under clinical development by Tianjin Hemay Pharmaceutical and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mufemilast’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mufemilast overview

Hemay-005 is under development for the treatment of moderate to severe ulcerative colitis, plaque psoriasis, atopic dermatitis, Behçet Disease and ankylosing spondylitis. It is administered through the oral route in the form of tablet and suspension. The therapeutic candidate acts by targeting phosphodiesterase 4 (PDE4). The drug candidate is a new chemical entity small molecule.

It was also under development for the treatment of Behçet Disease.

Tianjin Hemay Pharmaceutical overview

Tianjin Hemay Pharmaceutical (Hemay) discovers, develops and commercializes novel drugs to treat tumors and immune diseases. The company is investigating preclinical programs including Hemay102, a cyrotoxic anticancer agent targeting hepatocellular carcinoma (HCC); Hemay022, a tyrosine kinase irreversible inhibitor for the treatment of breast cancer; Hemay020, a tyrosince kinase irreversible inhibitor against non-small cell lung cancer (NSCLC); Hemay007, an immunomodulatory agent for Inflammatory Bowel Disease (IBD); and Hemay005, a PDE4 inhibitor to treat psoriasis. It is also evaluating Hemay805, a cytokine inhibitor for influenza, SARS, swine influenza and avian influenza. Hemay has research and development, operations and industrialization centers in Tianjin, Jiangxi, China; Australia and the US. Hemay is headquartered in Tianjin, China.

For a complete picture of Mufemilast’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.